Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Safety and Operational Efficiency of Restructuring and Redeploying a Transcatheter Aortic Valve Replacement Service During the COVID-19 Pandemic: The Oxford Experience

Jubin Joseph a, b, Rafail A. Kotronias a, b, Theodore Estrin-Serluia, Thomas J. Cahilla, Rajesh K. Kharbandaa, James D. Newton a, Catherine Grebenika, Sam Dawkins a, Adrian P. Banning a,⁎

a Oxford Heart Center, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
b Department of Cardiovascular Medicine, University of Oxford, Oxford, UK

Abstract

Article history:
Received 17 August 2020
Received in revised form 20 November 2020
Accepted 1 December 2020

Keywords:
Aortic stenosis
COVID-19
TAVR
Multidisciplinary Heart Team

Background: The risk of nosocomial COVID-19 infection for vulnerable aortic stenosis patients and intensive care resource utilization has led to cardiac surgery deferral. Untreated severe symptomatic aortic stenosis has a dismal prognosis. TAVR offers an attractive alternative to surgery as it is not reliant on intensive care resources. We set out to explore the safety and operational efficiency of restructuring a TAVR service and redeploying it to a new non-surgical site during the COVID-19 pandemic.

Methods: The institutional prospective service database was retrospectively interrogated for the first 50 consecutive elective TAVR cases prior to and after our institution’s operational adaptations for the COVID-19 pandemic. Our endpoints were VARC-2 defined procedural complications, 30-day mortality or re-admission and service efficiency metrics.

Results: The profile of patients undergoing TAVR during the pandemic was similar to patients undergoing TAVR prior to the pandemic with the exception of a lower mean age (79 vs 82 years, p < 0.01) and median EuroScore II (3.1% vs 4.6%, p = 0.01). The service restructuring and redeployment contributed to the pandemic-mandated operational efficiency with a reduction in the distribution of pre-admission hospital visits (3 vs 3 visits, p < 0.001) and the time taken from TAVR clinic to procedure (26 vs 77 days, p < 0.0001) when compared to the pre-COVID-19 service. No statistically significant difference was noted in peri-procedural complications and 30-day outcomes, while post-operative length of stay was significantly reduced (2 vs 3 days, p < 0.0001) when compared to pre-COVID-19 practice.

Conclusions: TAVR service restructuring and redeployment to align with pandemic-mandated healthcare resource rationalization is safe and feasible.

© 2020 Elsevier Inc. All rights reserved.

1. Background

The COVID-19 pandemic resulted in reorganization of healthcare systems and thousands of deaths worldwide [1]. On-going careful rationalization of healthcare services is required to streamline healthcare delivery and address urgent and emergent medical conditions that continue to progress.

Abbreviations: AS, Aortic stenosis; COVID-19, Coronavirus disease 2019; IQR, Interquartile range; MDT, Multidisciplinary team; NHS, National Health Service; sAVR, Surgical aortic valve replacement; TAVR, Transcatheter aortic valve replacement; VARC-2, Valve Academic Research Consortium - 2.

⁎ Corresponding author at: Oxford Heart Center, John Radcliffe Hospital, Headley Way, OX3 9DU Oxford, UK.
E-mail address: Adrian.Banning@ouh.nhs.uk (A.P. Banning).
1 These authors equally contributed to the manuscript.
not reliant on the need for postoperative ventilation and intensive care nursing.

Here, we describe the effect of the rapid introduction of a streamlined care pathway for patients with severe symptomatic AS undergoing TAVR during the COVID-19 pandemic at a site which had not previously performed transcatheter structural heart interventions.

2. Methods

2.1. Change in service

In response to NHS guidance and clinical demand for inpatient capacity at our tertiary center (John Radcliffe Hospital, Oxford UK), on the 27th March 2020 our TAVR service was asked to relocate to an adjacent local private hospital (The Nuffield Health Manor Hospital, Oxford UK) which had never performed transcatheter valvular heart intervention. This site is adjacent to the John Radcliffe but during the pandemic there was no intensive care or cardiac or vascular surgery on-site. This site did not accept acute admissions and all patients and staff were screened for temperatures and COVID-related symptoms prior to entry. The first TAVR was performed at this new site 4 days later on 31st March 2020. In addition to the relocation of the service, there was a change in pre- and post-procedural work-up and care which is illustrated in Fig. 1. In brief, following referral either direct for TAVR or from the urgent sAVR waiting list, the patient was triaged on the basis of high-risk features (Table 1), and if appropriate, invited for a single-stop elective outpatient visit during which consultation, transthoracic echocardiography and a gated TAVR-CT protocol were undertaken. If the latter ruled out significant proximal coronary disease an invasive angiogram was not performed. These data were presented remotely to the Heart Team via teleconferencing. If the patients were deemed technically suitable for transfemoral TAVR and clinically urgent, an elective admission to undertake TAVR was scheduled at the earliest timeslot available. All patients were asked to strictly "shield", as per government guidelines, for two-weeks prior to admission and if any COVID-19-related symptoms emerged during this time, or exposure to an individual suspected to have COVID-19, the planned admission was deferred. COVID-19 pre-operative screening was sparsely done due to the limited testing capacity at the time. Patients were admitted on the day of the procedure and transfemoral TAVR undertaken by our established structural heart catheterization laboratory team consisting of interventional cardiologists, one imaging cardiologist, an anaesthetist, two nurses, a cardiac physiologist and a radiographer. The team had migrated in unison from the tertiary center, where historically more than 1000 TAVRs have been performed. All patients received local anaesthesia with anaesthesia-led sedation. Patients were nursed on a standard ward with telemetry monitoring for rhythm disturbances. Early safe discharge was aimed for 24 h following the procedure in the absence of access site complications or conduction issues. Follow-up was performed at 30 days via telephone consultation.

2.2. Patient population

Patients were included if they underwent elective TAVR for the treatment of aortic stenosis. Patients were excluded if they were referred to the TAVR service greater than one year prior to the date of the planned procedure. The pre-COVID-19 period group consisted of 50 consecutive patients prior to relocation and reorganization of services (up to and including 27th March 2020). The COVID-19 period group consisted of 50 consecutive patients immediately following relocation and reorganization of services (after 27th March 2020). Data were retrospectively obtained from the institutional prospective service databases under audit authorization No 5172 from the Oxford University Hospitals NHS Foundation Trust.

2.3. TAVR procedure

All TAVR procedures used either the transfemoral at the new site or transaxillary access route at the surgical center. Transcatheter heart valve choice was at the operator’s discretion between those available at the center: Lotus Edge (Boston Scientific), Neo Acurate (Boston Scientific) and the SAPIEN 3 system (Edwards Lifescience). Balloon aortic valvuloplasty before and after TAVR was performed at the operator’s discretion when using the Lotus Edge and SAPIEN 3 system, it was mandated prior to insertion of the Neo Acurate valve. Patients received aspirin and clopidogrel after TAVR and were advised to continue taking these medications for at least 1 month after the

---

Table 1

| Clinical features | Echocardiography parameters |
|-------------------|-----------------------------|
| NYHA IV symptoms or recent admission with heart failure | Very high peak (≥125 mmHg)/mean (≥60 mmHg) gradients |
| Rapid deterioration in symptoms (3 months) | Severe left ventricular impairment (LVEF ≤30%) |
| Exertional syncope | Deteriorating left ventricular function (≥10% reduction in LVEF% from last documented study) |

LVEF: left ventricular ejection fraction; NYHA: New York Heart Association Classification.

---

Fig. 1. Patient pathway following referral for consideration of TAVR during the pre-COVID-19 period and following the COVID-19 adjustments.
procedure, in the absence of contraindication or concurrent anticoagulation.

2.4. Outcomes

The aim of this work was to describe the efficiency and safety of a streamlined TAVR patient pathway during the COVID-19 pandemic. We report logistic outcomes to measure efficiency, including time from referral to TAVR multidisciplinary team meeting (MDT), time from MDT to TAVR, TAVR-related number of hospital visits and length of stay. We report in-hospital and 30-day clinical outcomes to demonstrate safety according to VARC-2 standardised definitions, including death from any cause, neurological events, myocardial infarction, rehospitalisation, major vascular complication, significant bleeding, new onset atrial fibrillation and pacemaker insertion [6].

This work has not been powered to demonstrate differences in clinical outcomes. Continuous variables, which are presented as means with standard deviations or medians with interquartile ranges, were compared with the use of the Student’s t-test or the Wilcoxon rank-sum test. Categorical and ordinal variables, which are presented as proportions, were compared with the use of Fisher’s exact test or the Wilcoxon rank-sum test. All statistical analyses were performed with the use of SPSS 26.0 (IBM Inc. New York USA).

3. Results

3.1. Patients

Between 9th January 2020 and 26th March 2020, 50 patients underwent elective TAVR at the John Radcliffe Hospital, Oxford during the pre-COVID-19 period. Between 31st March 2020 and 3rd June 2020, 50 patients underwent elective TAVR at the Manor Hospital, Oxford during the COVID-19 period. Characteristics of the patients at baseline are described in Table 2. During the COVID-19 period there was a reduction in the mean age of patients undergoing TAVR (82 vs 79 years, p < 0.01) and a numerically small difference in median EuroScore II (4.6 vs 3.1%, p = 0.01). Despite this, patients were generally well matched for comorbidities, with the exception of more patients undergoing previous PCI in the pre-COVID-19 period (31 vs 9%, p < 0.01).

3.2. Pathway efficiency

Adoption of the COVID-19 period TAVR pathway resulted in changes in both the distribution of number of pre-admission hospital visits (3 IQR 3.4 vs 3 IQR 2.3, p < 0.001) and the time taken from TAVR clinic to procedure (77 vs 26 days, p < 0.0001) as demonstrated in Table 3. Furthermore, there was a significant reduction in the length of inpatient stay (3 vs 2 days, p < 0.0001).

3.3. Procedural outcomes

The procedural outcomes are demonstrated in Table 4. Despite transferring a TAVR service in a new setting, there was no significant difference in the distribution of procedure length during the COVID-19 pandemic (60 vs 60 min, p = 0.18). There was a significant increase in the proportion of Sapien 3 valves inserted (34 vs 68%, p = 0.001). Post-procedural haemodynamic values in both groups are consistent with those seen in previously published data. There was no severe post-procedural aortic regurgitation in either group.

3.4. In-hospital and 30-day clinical outcomes (safety analysis)

In-hospital and 30 days outcome data are shown in Table 5. There was no statistically relevant difference between the two treatment periods in the incidence of death or disabling stroke, but there were numerically more minor strokes during the COVID-19 period. No vascular complications required vascular surgery and they were managed successfully with established percutaneous techniques [7]. One death in the COVID-19 period group post discharge was unrelated to the TAVR procedure and not due to cardiovascular pathology. There was a non-significant reduction in the number of pacemakers inserted following a TAVR procedure in the COVID-19 period group compared to the pre-COVID-19 group.

4. Discussion

There are three main findings of our work. Firstly, an experienced TAVR team can be safely redeployed in less than a week to a new hospital site to rapidly deliver a safe and effective TAVR service. Secondly, a streamlined TAVR patient pathway can reduce the number of hospital visits and length of inpatient stay during the COVID-19 pandemic. Thirdly, TAVR can be undertaken safely during the COVID-19 pandemic with 30-day event rates similar to those published in clinical trials and international registries.

4.1. Balancing the risks of severe AS and COVID-19

Patients with severe AS are usually elderly with significant comorbidity, who are those most susceptible to adverse outcomes following COVID-19 infection. There has been significant concern about the risk of admitting this population electively to hospital during the ongoing pandemic, given the risk of nosocomial COVID-19 infection in these vulnerable patients [8]. Counter to this, is the risk of the morbidity and mortality that is frequently seen when symptomatic severe aortic stenosis is left untreated [3]. Our triaging practice closely aligned with

---

Table 2: Characteristics of the patients at baseline.

| Characteristic                  | Pre-COVID-19 era (n = 50) | COVID-19 era (n = 50) |
|--------------------------------|---------------------------|----------------------|
| **Clinical**                   |                           |                      |
| Age - years                    | 82 ± 6                    | 79 ± 7               |
| Male sex – %                   | 74                        | 56                   |
| Height - m                     | 1.7 ± 0.1                 | 1.6 ± 0.1            |
| Weight – kg                    | 78 ± 16                   | 85 ± 15              |
| Body mass index – no. [IQR]    | 27 (25, 29)               | 29 (28, 34)          |
| Euroscore II – % [IQR]         | 4.6 (3.0, 9.0)            | 3.1 (1.8, 5.4)       |
| NYHA Class – average           | 3 (3.3)                   | 3 (3.3)              |
| Coronary artery disease – %    | 41                        | 31                   |
| Previous myocardial infarction - % | 15                    | 9                    |
| Previous PCI - %               | 31                        | 9                    |
| Cerebral vascular disease - %  | 20                        | 11                   |
| Peripheral vascular disease - %| 64                        | 44                   |
| Extracardiac arteriopathy - %  | 64                        | 44                   |
| Calciumisation of ascending aorta - % | 8                   | 0                    |
| Atrial fibrillation - %        | 22                        | 30                   |
| Permanent pacemaker - %        | 14                        | 8                    |
| Diabetes mellitus - %          | 25                        | 24                   |
| Current smoker - %             | 6                         | 2                    |
| COPD - %                       | 15                        | 11                   |
| Oxygen-dependent - %           | 2                         | 2                    |
| Poor mobility - %              | 70                        | 54                   |
| Liver disease - %              | 4                         | 4                    |
| **Laboratory**                 |                           |                      |
| Haemoglobin – g/dL             | 126 ± 18                  | 132 ± 20             |
| Platelets                      | 217 ± 69                  | 206 ± 65             |
| Creatinine                     | 89 (79, 111)              | 88 (70, 109)         |
| Serum albumin <3.5 g/dL - %    | 26                        | 7                    |
| **Echocardiography**           |                           |                      |
| Aortic valve area (cm²)        | 0.6 (0.5, 0.8)            | 0.7 (0.6, 0.8)       |
| Mean gradient (mmHg)           | 43 ± 12                   | 48 ± 13              |
| Peak gradient (mmHg)           | 70 (65, 86)               | 77 (65, 103)         |
| LV EF <50% - %                 | 30                        | 14                   |
| Mitral regurgitation >moderate - % | 28                   | 20                   |

COPD: chronic obstructive pulmonary disease; IQR: interquartile range; LVEF: left ventricular ejection fraction; PCI: percutaneous coronary intervention.
the subsequently published ACC/SCAI position statement [9]. However, our practice was less restrictive than the Canadian Association of Interventional Cardiology proposed practice framework – though the implementation of their recommendations allowed for regional interpretive flexibility [10]. These data demonstrate that despite the infection risk and healthcare resource challenges during the current pandemic, TAVR can be safely and effectively delivered to selected patients on an elective basis during the COVID-19 pandemic with results similar to the contemporary literature [11–14].

4.2. Service restructuring considerations

In the context of a pandemic, there is a significant challenge to delivery of cardiovascular healthcare to vulnerable patients during a time when resources are being diverted to prevent critical services being overwhelmed. We used innovative telehealth clinics to assess symptom overwhelmed. We used innovative telehealth clinics to assess symptom

Table 3
Efficiency metrics of the TAVR pathway.

|                          | Pre-COVID-19 era (n = 50) | COVID-19 era (n = 50) | p-Value  |
|--------------------------|---------------------------|-----------------------|----------|
| Number of hospital visits|                           |                       | <0.001   |
| - Median (Interquartile range) | 3 (2, 3)                  | 3 (2, 3)              |          |
| Time from referral to TAVR clinic | 35 (11, 59)             | 32 (22, 57)          | 0.45     |
| - Median days (Interquartile range) | 17 (15, 23)            | 15 (12, 22)          |          |
| Time from TAVR clinic to TAVR | 77 (44, 91)             | 26 (13, 65)          | <0.0001  |
| - Median days (Interquartile range) | 3 (2, 3)                 | 2 (1, 2)             | <0.0001  |

4.3. TAVR during the COVID-19 pandemic

Length of stay associated with TAVR procedures has gradually shortened over time, and early discharge has been shown to be safe in select patients [18]. To facilitate early discharge [9,10,16], we admitted patients on the day of the procedure and predominantly chose an

Table 4
Procedural Outcomes of TAVR.

|                          | Pre-COVID-19 era (n = 50) | COVID-19 era (n = 50) |
|--------------------------|---------------------------|-----------------------|
| Percutaneous access - %  |                           |                       |
| Femoral                  | 98                        | 100                   |
| Axillary                 | 2                         | 0                     |
| Valve type (%)           |                           |                       |
| Lotus Edge               | 40                        | 12                    |
| Neo Acurate              | 26                        | 20                    |
| Sapien 3                 | 34                        | 68                    |
| Anaesthetic %            |                           |                       |
| General anaesthetic      | 4                         | 2                     |
| Sedation                 | 96                        | 98                    |
| Procedure time – min     | 60 (60, 80)               | 60 (60, 80)           |
| BAV before valve deployment - % | 39                      | 24                    |
| Post deployment aortic valve peak gradient - mmHg | 11 (8, 15) | 12 (10, 16) |
| Post deployment aortic valve mean gradient - mmHg | 5 (5, 8) | 6 (5, 8) |
| Post deployment aortic valve area - (cm²) | 2.0 (1.8, 2.0) | 2.0 (1.8, 2.0) |
| Aortic regurgitation following procedure - %  |                       |                       |
| Mild                     | 18                        | 16                    |
| Moderate                 | 4                         | 0                     |
| Severe                   | 0                         | 0                     |

BAV: balloon aortic valvuloplasty.
anatomically suitable valve prosthesis associated with the lowest risk of requiring subsequent permanent cardiac pacing. During the COVID-19 pandemic patients were younger and had lower calcification burden compared to our pre-pandemic practice. Their suitability for the Sapien 3 prosthesis; a prosthesis with a lower risk for permanent pacemaker implantation [19], accounts for the change in the ratio of prostheses implanted [19], and is not powered to identify difference in outcomes. Therefore, our results should be considered as pilot data requiring larger datasets to establish outcome non-inferiority. However, the incorporation of the service changes described above has the potential to further improve the cost-effectiveness of a TAVR service. The COVID-19 pandemic has acted as a catalyst for change in healthcare systems worldwide. The resulting adaptations ought to be perceived as opportunities for sustained change and not as temporary disruptions to an often empirically derived TAVR service framework. In this regard, once we have overcome the COVID-19 pandemic a wider consultation process on the future of healthcare delivery models should be considered.

5. Limitations

Our work focuses on describing a model of rapid restructuring and deployment of an established TAVR service in the context of a pandemic and is not powered to identify difference in outcomes. Therefore, our results should be interpreted as pilot data requiring larger datasets to establish outcome non-inferiority. However, the incorporation of complications and improvements in time derived efficiency metrics are within plausible ranges.

6. Conclusion

In the context of the COVID-19 pandemic, TAVR can be undertaken safely in selected patients on an elective basis with a similar safety profile to routine pre-COVID-19 practice. Moreover, we show that a TAVR service can be rapidly restructured and streamlined to align with pandemic-mandated operational efficiency through reduction in hospital visits and post-operative length of stay. Finally, rapid redeployment of a TAVR team to a new site is feasible and contributes to a safe and effective service delivery during a pandemic. The features of safety, adaptability and flexibility are of paramount importance for the continuation of the TAVR service in a pandemic period. The changes to enable the continuation of TAVR during the pandemic can inform our post-pandemic practice.

CRediT authorship contribution statement

Jubin Joseph: Methodology, Investigation, Data curation, Formal analysis, Visualization, Writing - original draft, Writing - review & editing. Rafail A. Kotronias: Methodology, Investigation, Data curation, Formal analysis, Visualization, Writing - original draft, Writing - review & editing. Theodore Estrin-Serlui: Investigation, Data curation, Writing - review & editing. Thomas J. Cahill: Writing - review & editing. Catherine Grebeniuk: Writing - review & editing. Sam Dawkins: Writing - review & editing. Adrian P. Banning: Conceptualization, Methodology, Writing - review & editing, Supervision.

Declaration of competing interest

Adrian P. Banning reports grants from Boston Scientific, personal fees from Boston Scientific, personal fees from Abbott, personal fees from Medtronic, personal fees from Phillips, outside the submitted work; Rajesh K. Kharbanda reports personal fees from Boston Scientific, during the conduct of the work; Adrian P. Banning & Rajesh K. Kharbanda are partially funded by the NHS NIHR Biomedical Research Center, Oxford; Rafail A Kotronias’s post is funded by the National Institute for Health Research. The rest of the authors have no conflict of interest to declare.

Acknowledgements

The authors would like to acknowledge the John Radcliffe Hospital Catheterization laboratory and TAVR administrative teams and the Manor Hospital Nursing and administrative teams for their tireless work in supporting the restructuring and redeployment of the TAVR service. The incorporation of the service changes described above has the potential to further improve the cost-effectiveness of a TAVR service.

References

[1] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
[2] Sengelen M, Cheng S, Bolognese T, Matsushita K, Konyet S, Solomon SD, et al. Ideal cardiovascular health and the prevalence and severity of aortic stenosis in elderly patients. J Am Heart Assoc. 2018;7(3):e007234.
[3] Caraballo BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373(9667):956–66.
[4] Marquis-Gravel G, Redfors B, Leon MB, Généreux P. Medical treatment of aortic stenosis. Circulation. 2016;134(22):1766–84.
[5] NHS England, NHS Improvement. Clinical guide for the management of cardiology patients during the coronavirus pandemic; 2020 [NHS England].
[6] Kaptein et al. AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg. 2012;42(3):S54–60.
[7] Scarinci R, De Maria GL, Joseph J, Fan L, Cahill TJ, Kotronias RA, et al. Impact of complications during transfemoral transcatheter aortic valve replacement: how can they be avoided and managed? J Am Heart Assoc. 2019;8(18):e013801.
[8] Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of healthcare workers for SAR-CoV-2: highlights the role of asymptomatic carriage in COVID-19 transmission. Elife. 2020;9:e58728.
[9] Shah PB, Welt FGP, Mahmud E, Phillips A, Kleiman NS, Young MN, et al. Triage considerations for patients referred for structural heart disease intervention during the COVID-19 pandemic: an ACC/SCAI position statement. Catheter Cardiovasc Interv. 2020;96(3):559–63.
[10] Wood DA, Sathananthan J, Gin K, Mansour S, Ly HQ, Quraishi AU, et al. Precautions and procedures for coronary and structural cardiac interventions during the COVID-19 pandemic: guidance from Canadian Association of Interventional Cardiology. Can J Cardiol. 2020;36(5):780–3.
[11] Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1567–77.
[12] Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5-Year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2477–84.
Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380(18):1695–705.

Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, et al. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med. 2020;382(9):799–809.

Chung CJ, Nazif TM, Wolbinski M, Hakemi E, Lebehn M, Brandwein R, et al. Restructuring structural heart disease practice during the COVID-19 pandemic: JACC review topic of the week. J Am Coll Cardiol. 2020;75(23):2974–83.

Khan JM, Khalid N, Shlofmitz E, Forrestal BJ, Yerasi C, Case BC, et al. Guidelines for balancing priorities in structural heart disease during the COVID-19 pandemic. Cardiovasc Revasc Med. 2020;21(8):1030–3.

Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis. Epidemiol Rev. 2001;23(2):288–301.

Kotronias RA, Teitelbaum M, Webb JC, Mylotte D, Barbanti M, Wood DA, et al. Early versus standard discharge after transcatheter aortic valve replacement: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2018;11(17):1759–71.

van Gils L, Tchetche D, Lhermusier T, Abawi M, Dumonteil N, Rodriguez Olivares R, et al. Transcatheter heart valve selection and permanent pacemaker implantation in patients with pre-existing right bundle branch block. J Am Heart Assoc. 2017;6(3).

Kotronias RA, Scarsini R, De Maria GL, Rajasundaram S, Sayeed R, Krasopoulos G, et al. Ultrasound guided vascular access site management and left ventricular pacing are associated with improved outcomes in contemporary transcatheter aortic valve replacement: insights from the OxTAVI registry. Catheter Cardiovasc Interv. 2020;96(2):432–9.

Tam DY, Azizi PM, Chikwe J, Gaudino M, Wijeysundera HC. The cost-effectiveness of transcatheter aortic valve replacement in low surgical risk patients with severe aortic stenosis. Eur Heart J Qual Care Clin Outcomes. 2020 July 9. https://doi.org/10.1093/ehjqcco/qcaa058 [Article in press].